Myocardial remodeling: Cellular and extracellular events and targets

Annual Review of Physiology

Volumn 73, Issue , 2011, Pages 47-68

  Dixon, Jennifer A ^a,b   Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

large animal models; matrix metalloproteinases; myocardial infarction

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PLACEBO; PROTEINASE; SCLEROPROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); ENGRAFTMENT; ENZYME ACTIVATION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; EXTRACELLULAR SPACE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; SHEEP; SIGNAL TRANSDUCTION; STEM CELLS; SWINE; VENTRICULAR REMODELING;

EID: 79951778377     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-012110-142230     Document Type: Article

References (136)

1. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, et al. 2004. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 43:2207-15 (Pubitemid 38757586)
2. Lam CS, Grewal J, Borlaug BA, Ommen SR, Kane GC, et al. 2010. Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. Hypertension 55:1143-49
3. Mann DL, Bristow MR. 2005. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837-49 (Pubitemid 40791557)
4. Li L, Okada H, Takemura G, Kosai K, Kanamori H, et al. 2009. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. Am. J. Physiol. Heart Circ. Physiol. 297:1504-13
5. Stewart JA Jr, Massey EP, Fix C, Zhu J, Goldsmith EC, Carver W. 2010. Temporal alterations in cardiac fibroblast function following induction of pressure overload. Cell Tissue Res. 340:117-26
6. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, et al. 2006. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem. Biophys. Res. Commun. 340:1125-33 (Pubitemid 43083395)
7. Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, et al. 2007. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Investig. 117:1782-93 (Pubitemid 47036312)
8. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, et al. 2009. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104:170-78
9. Ryan TD, Rothstein EC, Aban I, Tallaj JA, Husain A, et al. 2007. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. J. Am. Coll. Cardiol. 49:811-21 (Pubitemid 46240707)
10. Brown JH, Del Re DP, Sussman MA. 2006. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. 98:730-42
11. Ferrari R, Ceconi C, Campo G, Cangiano E, Cavazza C, et al. 2009. Mechanisms of remodelling: a question of life (stem cell production) and death (myocyte apoptosis). Circ. J. 73:1973-82
12. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, et al. 2005. Mobilization of bone marrowderived stem cells after myocardial infarction and left ventricular function. Eur. Heart J. 26:1196-204 (Pubitemid 40863126)
13. Leone AM, Rutella S, Bonanno G, Contemi AM, de Ritis DG, et al. 2006. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int. J. Cardiol. 111:202-8 (Pubitemid 44107557)
14. Wojakowski W, TenderaM, Kucia M, Zuba-Surma E, Paczkowska E, et al. 2009. Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 53:1-9
15. Wojakowski W, Tendera M, Michaowska A, Majka M, Kucia M, et al. 2004. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110:3213-20 (Pubitemid 39525068)
16. Wojakowski W, Tendera M, Zebzda A, Michaöwska A, Majka M, et al. 2006. Mobilization of CD34+, CD117+, CXCR4+, c-met+ stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur. Heart J. 27:283-89 (Pubitemid 43100022)
17. Shintani S, MuroharaT, Ikeda H, Ueno T, HonmaT, et al. 2001. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103:2776-79 (Pubitemid 32550062)
18. Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, et al. 2005. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112:3097-106 (Pubitemid 43113441)
19. Kuethe F, Figulla HR, Herzau M, Voth M, Fritzenwanger M, et al. 2005. Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am. Heart J. 150:115
20. Leone AM, Galiuto L, Garramone B, Rutella S, Giannico MB, et al. 2007. Usefulness of granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the Rigenera study). Am. J. Cardiol. 100:397-403 (Pubitemid 47094686)
21. Takano H, Hasegawa H, Kuwabara Y, Nakayama T, Matsuno K, et al. 2007. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int. J. Cardiol. 122:41-47 (Pubitemid 47503345)
22. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. 2001. Bone marrow cells regenerate infarcted myocardium. Nature 410:701-5 (Pubitemid 32290358)
23. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. 1998. Myocyte proliferation in end-stage cardiac failure in humans. Proc. Natl. Acad. Sci. USA 95:8801-5 (Pubitemid 28350569)
24. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. 2004. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428:668-73 (Pubitemid 38524811)
25. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, et al. 2004. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428:664-68 (Pubitemid 38524810)
26. Hill JM, Dick AJ, Raman VK, Thompson RB, Yu ZX, et al. 2003. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 108:1009-14 (Pubitemid 37048233)
27. Johnsen HE. 2001. Clinical practice and future needs in recombinant human granulocyte colonystimulating factor treatment: a review of randomized trials in clinical haemato-oncology. J. Int. Med. Res. 29:87-99 (Pubitemid 32471873)
28. KraitchmanDL, Heldman AW, Atalar E, Amado LC, Martin BJ, et al. 2003. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107:2290-93 (Pubitemid 36578497)
29. Norol F, Merlet P, Isnard R, Sebillon P, Bonnet N, et al. 2003. Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood 102:4361-68 (Pubitemid 37494096)
30. Stodilka RZ, Blackwood KJ, Kong H, Prato FS. 2006. A method for quantitative cell tracking using SPECT for the evaluation of myocardial stem cell therapy. Nucl. Med. Commun. 27:807-13 (Pubitemid 44401250)
31. Scott BL, Estey E. 2008. Management of myelodysplastic syndromes: 2008 update. Oncology 22:1344-52
32. Iwanaga K, Takano H, Ohtsuka M, Hasegawa H, Zou Y, et al. 2004. Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem. Biophys. Res. Commun. 325:1353-59 (Pubitemid 39535912)
33. Ellis SG, PennMS, Bolwell B, Garcia M, Chacko M, et al. 2006. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am. Heart J. 152:1051.e9-14
34. Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, et al. 2006. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the GCSF- STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol. 48:1712-21 (Pubitemid 44528196)
35. Ripa RS, Jgensen E, Wang Y, Thune JJ, Nilsson JC, et al. 2006. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute STelevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113:1983-92
36. Zohlnhöfer D, Dibra A, Koppara T, de Waha A, Ripa RS, et al. 2008. Stem cell mobilization by granulocyte colony-stimulating factor formyocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51:1429-37 (Pubitemid 351470028)
37. Zohlnhöfer D, Dibra A, Koppara T, de Waha A, Ripa RS, et al. 2008. Stem cell mobilization by granulocyte colony-stimulating factor formyocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51:1429-37
38. Zohlnhöfer D. 2008. G-CSF for left ventricular recovery after myocardial infarction: Is it time to face reality? Cardiovasc. Drugs Ther. 22(5):343-45
39. Sanganalmath SK, Stein AB, Guo Y, Tiwari S, Hunt G, et al. 2009. The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. J. Mol. Cell Cardiol. 47:528-35
40. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-67 (Pubitemid 27087709)
41. Henning RJ, Burgos JD, Ondrovic L, Sanberg P, Balis J, Morgan MB. 2006. Human umbilical cord blood progenitor cells are attracted to infarctedmyocardium and significantly reducemyocardial infarction size. Cell Transplant. 15:647-58 (Pubitemid 44904676)
42. Leor J, Guetta E, Feinberg MS, Galski H, Bar I, et al. 2006. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells 24:772-80 (Pubitemid 44464782)
43. Kamihata H, Matsubara H, NishiueT, Fujiyama S, Tsutsumi Y, et al. 2001. Implantation of bonemarrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104:1046-52 (Pubitemid 32803883)
44. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, et al. 2001. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA 98:10344-49 (Pubitemid 32803022)
45. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, et al. 2004. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95:911-21 (Pubitemid 39435006)
46. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, et al. 2003. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA 100:12313-18 (Pubitemid 37271557)
47. Qian L, Srivastava D. 2010. Monkeying around with cardiac progenitors: hope for the future. J. Clin. Investig. 120(4):1034-36
48. Mazhari R, Hare JM. 2007. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1):21-26
49. BrehmM, Ebner P, Picard F, Urbien R, Turan G, Strauer BE. 2009. Enhanced mobilization of CD34+ progenitor cells expressing cell adhesion molecules in patients with STEMI. Clin. Res. Cardiol. 98:477-86
50. Hristov M, WeberC. 2004. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J. Cell Mol. Med. 8:498-508 (Pubitemid 44145482)
51. Rafii S, Lyden D. 2003. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9:702-12 (Pubitemid 36749219)
52. Jujo K, Ii M, Losordo DW. 2008. Endothelial progenitor cells in neovascularization of infarcted myocardium. J. Mol. Cell Cardiol. 45:530-44
53. Freyman T, Polin G, Osman H, Crary J, Lu M, et al. 2006. A quantitative, randomized study evaluating threemethods of mesenchymal stem cell delivery following myocardial infarction. Eur. Heart J. 27:1114-22
54. Moelker AD, Baks T, Wever KM, Spitskovsky D, Wielopolski PA, et al. 2007. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J. Mol. Cell Cardiol. 42:735-45 (Pubitemid 46533979)
55. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, et al. 2007. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur. Heart J. 28:2667-77 (Pubitemid 350071533)
56. Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, et al. 2001. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J. Am. Coll. Cardiol. 37:1726-32
57. Perin EC, SilvaGV, Assad JA, Vela D, Buja LM, et al. 2008. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J. Mol. Cell Cardiol. 44:486-95 (Pubitemid 351374698)
58. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, et al. 2005. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl. Acad. Sci. USA 102:11474-79 (Pubitemid 41153844)
59. Dixon JA, Gorman RC, Stroud RE, Bouges S, Hirotsugu H, et al. 2009. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation 120(Suppl. 11):220-29
60. Hamamoto H, Gorman JH 3rd, Ryan LP, Hinmon R, Martens TP, et al. 2009. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann. Thorac. Surg. 87:794-801
61. Jameel MN, Li Q, Mansoor A, Qiang X, Sarver A, et al. 2010. Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 298:1348-56
62. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, et al. 2002. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73:1919-25
63. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, et al. 2005. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111:150-56 (Pubitemid 40139725)
64. Mäkelä J, Ylitalo K, Lehtonen S, Dahlbacka S, Niemelä E, et al. 2007. Bone marrow-derived mononuclear cell transplantation improves myocardial recovery by enhancing cellular recruitment and differentiation at the infarction site. J. Thorac. Cardiovasc. Surg. 134:565-73 (Pubitemid 47301958)
65. de Silva R, Raval AN, Hadi M, Gildea KM, Bonifacino AC, et al. 2008. Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis productmay not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarction. Eur. Heart J. 29:1772-82 (Pubitemid 352019815)
66. Schuleri KH, FeigenbaumGS, CentolaM, Weiss ES, Zimmet JM, et al. 2009. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur. Heart J. 30:2722-32
67. Guhathakurta S, Subramanyan UR, Balasundari R, Das CK, Madhusankar N, Cherian KM. 2009. Stem cell experiments and initial clinical trial of cellular cardiomyoplasty. Asian Cardiovasc. Thorac. Ann. 17:581-86
68. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, et al. 2009. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 120:1075-83
69. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, et al. 2002. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15):1913-18 (Pubitemid 35176294)
70. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, et al. 2002. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24):3009-17 (Pubitemid 35440281)
71. Kuethe F, Richartz BM, Sayer HG, Kasper C, Werner GS, et al. 2004. Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans with large anterior myocardial infarctions. Int. J. Cardiol. 97(1):123-27 (Pubitemid 39178533)
72. Chen SL, FangWW, Ye F, LiuYH, Qian J, et al. 2004. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 94(1):92-95
73. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, et al. 2004. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429):141-48 (Pubitemid 38891685)
74. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, et al. 2005. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 112(Suppl. 9):I178-83 (Pubitemid 41266671)
75. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, et al. 2006. Autologous bone marrowderived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505):113-21 (Pubitemid 43077127)
76. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, et al. 2006. Intracoronary injection ofmononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12):1199-209 (Pubitemid 44427444)
77. Yousef M, Schannwell CM, Köstering M, Zeus T, BrehmM, Strauer BE. 2009. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 53(24):2262-69
78. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, et al. 2009. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 30(24):2978-84
79. Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, et al. 2009. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart 95(24):1983-89
80. Jugdutt BI, Joljart MJ, Khan MI. 1996. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation 94:94-101 (Pubitemid 126426405)
81. See F, Kompa A, Martin J, Lewis DA, Krum H. 2005. Fibrosis as a therapeutic target postmyocardial infarction. Curr. Pharm. Des. 11:477-87 (Pubitemid 40207758)
82. Villarreal F, Omens J, Dillmann W, Risteli J, Nguyen J, Covell J. 2004. Early degradation and serum appearance of type I collagen fragments after myocardial infarction. J. Mol. Cell Cardiol. 36:597-601 (Pubitemid 38469950)
83. Blom AS, Pilla JJ, Arkles J, Dougherty L, Ryan LP, et al. 2007. Ventricular restraint prevents infarct expansion and improves borderzone function aftermyocardial infarction: a study usingmagnetic resonance imaging, three-dimensional surface modeling, and myocardial tagging. Ann. Thorac. Surg. 84:2004-10 (Pubitemid 350123737)
84. Wang Y, SunW, Cao G, Meng L, Song L, Du X. 2006. Delayed hyperenhancement patterns in occlusive and reperfusedmyocardial infarcts during different healing stages. J. Magn. Reson. Imaging. 24(4):851-57 (Pubitemid 44546997)
85. Lee AA, Delhaas T, McCulloch AD, Villarreal FJ. 1999. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns. J. Mol. Cell Cardiol. 31:1833-43 (Pubitemid 29460017)
86. Lerman RH, Apstein CS, Kagan HM, Osmers EL, Chichester CO, et al. 1983. Myocardial healing and repair after experimental infarction in the rabbit. Circ. Res. 53:378-88 (Pubitemid 13012420)
87. MacKenna D, Summerour SR, Villarreal FJ. 2000. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc. Res. 46:257-63 (Pubitemid 30204597)
88. Zimmerman SD, Criscione J, Covell JW. 2004. Remodeling in myocardium adjacent to an infarction in the pig left ventricle. Am. J. Physiol. Heart Circ. Physiol. 287:2697-704
89. Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. 1995. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J. Am. Coll. Cardiol. 25:567-73
90. Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH. 1984. Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. J. Am. Coll. Cardiol. 4:201-208 (Pubitemid 14053542)
91. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, et al. 2003. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107(4):618-25 (Pubitemid 36176814)
92. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. 1987. Left ventricular endsystolic volume as themajor determinant of survival after recovery frommyocardial infarction. Circulation 76:44-51 (Pubitemid 17093191)
93. Spinale FG. 2007. Myocardial matrix remodeling and thematrixmetalloproteinases: influence on cardiac form and function. Physiol. Rev. 87(4):1285-342 (Pubitemid 350041472)
94. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477:267-83 (Pubitemid 30119906)
95. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. 1992. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem. 267:17321-26
96. Yang TT, Hawkes SP. 1992. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 89:10676-80
97. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. 1997. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem. 272:15496-500 (Pubitemid 27255577)
98. Stratmann B, Farr M, Tschesche H. 2001. MMP-TIMP interaction depends on residue 2 in TIMP-4. FEBS Lett. 507:285-87 (Pubitemid 33030250)
99. Vanhoutte D, Heymans S. 2010. TIMPs and cardiac remodeling: "embracing the MMP-independentside of the family." J. Mol. Cell Cardiol. 48(3):445-53
100. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, et al. 1997. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 78(3):278-84 (Pubitemid 27431737)
101. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. 2001. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 141(2):211-17 (Pubitemid 32128725)
102. Inoue T, Kato T, Takayanagi K, Uchida T, Yaguchi I, et al. 2003. Circulatingmatrixmetalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am. J. Cardiol. 92(12):1461-64 (Pubitemid 37532574)
103. Kaden JJ, Dempfle CE, Sueselbeck T, Brueckmann M, Poerner TC, et al. 2003. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 99(3):140-44 (Pubitemid 36736956)
104. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, et al. 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32(2):368-72 (Pubitemid 28396484)
105. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, et al. 2007. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart J. 28(6):711-18 (Pubitemid 46439245)
106. Lalu MM, Pasini E, Schulze CJ, Ferrari-VivaldiM, Ferrari-VivaldiG, et al. 2005. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur. Heart J. 26(1):27-35 (Pubitemid 40221120)
107. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, et al. 2005. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int. J. Cardiol. 105(2):203-8 (Pubitemid 41512488)
108. Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, et al. 2005. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int. J. Cardiol. 105(1):67-73 (Pubitemid 41406362)
109. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. 2004. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J. Card. Fail. 10(4):328-33 (Pubitemid 39092685)
110. Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. 2005. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am. J. Cardiol. 96(1):31-34 (Pubitemid 40853935)
111. Wagner DR, Delagardelle C, Ernens I, Rouy D, VaillantM, Beissel J. 2006. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J. Card. Fail. 12(1):66-72 (Pubitemid 43267754)
112. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, et al. 2006. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114(10):1020-27 (Pubitemid 44358878)
113. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, et al. 2007. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin. Sci. 112(1):43-49 (Pubitemid 46120084)
114. Furenes EB, Arnesen H, Solheim S, Gräard HK, Hoffmann P, Seljeflot I. 2009. The profile of circulatingmetalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb. Res. 124(5):560-64
115. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, et al. 2008. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur. Heart J. 9(17):2116-24
116. Moon SK, Cha BY, Kim CH. 2004. ERK1/2 mediates TNF-α-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-κB and AP-1: involvement of the ras dependent pathway. J. Cell Physiol. 198(3):417-27
117. Galis ZS, Sukhova GK, Lark MW, Libby P. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Investig. 94(6):2493-503 (Pubitemid 24379627)
118. Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, et al. 2010. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int. J. Cardiol. In press
119. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. 2004. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109(23):2850-56
120. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. 2004. Relations of plasma totalTIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J. 25(17):1509-16
121. Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, et al. 2001. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am. J. Physiol. Heart Circ. Physiol. 281(3):987-94
122. Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, et al. 2003. Region- and typespecific induction of matrix metalloproteinases in postmyocardial infarction remodeling. Circulation 107(22):2857-63 (Pubitemid 36705998)
123. Apple KA, Yarbrough WM, Mukherjee R, Deschamps AM, Escobar PG, et al. 2006. Selective targeting of matrix metalloproteinase inhibition in postinfarctionmyocardial remodeling. J. Cardiovasc. Pharmacol. 47(2):228-35 (Pubitemid 44384061)
124. Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, et al. 2006. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 290(6):2522-27
125. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, et al. 2003. Selective targeting and timing of matrix metalloproteinase inhibition in
126. Peterson JT. 2006. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69(3):677-87 (Pubitemid 43139730)
127. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, et al. 2006. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. 48(1):15-20 (Pubitemid 43929218)
128. King MK, Coker ML, Goldberg A, McElmurray JH 3rd, Gunasinghe HR, et al. 2003. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ. Res. 92(2):177-85 (Pubitemid 36258360)
129. Butler D. 2008. Translational research: crossing the valley of death. Nature 453(7197):840-42 (Pubitemid 351832542)
130. Jugdutt BI. 2008. Aging and remodeling during healing of the wounded heart: current therapies and novel drug targets. Curr. Drug Targets 9:325-44 (Pubitemid 351836433)
131. Jugdutt BI, Jelani A, Palaniyappan A, Idikio H, Uweira RE, et al. 2010. Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model. Effect of early therapy with an angiotensin II type I receptor blocker. Circulation 122(4):341-51
132. Jugdutt BI, Palaniyappan A, Uwiera RR, Idikio H. 2009. Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol. Cell Biochem. 322(1-2):25-36
133. Deschamps AM, Zavadzkas J, MurphyRL, KovalCN, McLean JE, et al. 2008. Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 294(2):875-83
134. Mias C, Lairez O, Trouche E, Roncalli J, Calise D, et al. 2009. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis aftermyocardial infarction. Stem Cells 27(11):2734-43
135. Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maestroni S, et al. 2008. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ. Res. 103(1):107-16
136. Qi CM, Ma GS, Liu NF, Shen CX, Chen Z, et al. 2008. Transplantation of magnetically labeled mesenchymal stem cells improves cardiac function in a swine myocardial infarction model. Chin. Med. J. 121(6):544-50 (Pubitemid 351479636)